-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 4, 2022, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Center issued a notice on supplementing the online purchase of Glimepiride tablets by Shandong Xinhua Pharmaceutical Co.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
According to the notice, according to the "Announcement on Cancelling the Selection of Glimepiride Tablets of Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
and Putting the Enterprise on the Violation List" issued by theNational Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
, Ltd.
and Putting the Enterprise on the Violation List" issued by theNational Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
In accordance with the relevant provisions of the "National Centralized Drug Procurement Document (GY-YD2019-2)" of the Joint Procurement Office, Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
On January 29, 2022, the State-organized Drug Joint Procurement Office issued an announcement stating that the results of the second batch of state-organized centralized drug procurement have been launched in various places in April 2020
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
On February 23, 2022, Shanghai Sunshine Pharmaceutical Purchasing Network announced that the glimepiride tablets previously produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
The supply of pharmaceutical substitutes will be officially implemented on March 1
.
The supply of pharmaceutical substitutes will be officially implemented on March 1
.
On March 4, 2022, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Center issued a notice on supplementing the online purchase of Glimepiride tablets by Shandong Xinhua Pharmaceutical Co.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
According to the notice, according to the "Announcement on Cancelling the Selection of Glimepiride Tablets of Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
and Putting the Enterprise on the Violation List" issued by the National Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
, Ltd.
and Putting the Enterprise on the Violation List" issued by the National Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
In accordance with the relevant provisions of the "National Centralized Drug Procurement Document (GY-YD2019-2)" of the Joint Procurement Office, Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
On January 29, 2022, the State-organized Drug Joint Procurement Office issued an announcement stating that the results of the second batch of state-organized centralized drug procurement have been launched in various places in April 2020
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
On February 23, 2022, Shanghai Sunshine Pharmaceutical Purchasing Network announced that the glimepiride tablets previously produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
The supply of pharmaceutical substitutes will be officially implemented on March 1
.
The supply of pharmaceutical substitutes will be officially implemented on March 1
.
On March 4, 2022, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Center issued a notice on supplementing the online purchase of Glimepiride tablets by Shandong Xinhua Pharmaceutical Co.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
, Ltd.
(Jin Yaozhao [2022] No.
20)
.
According to the notice, according to the "Announcement on Cancelling the Selection of Glimepiride Tablets of Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
and Putting the Enterprise on the Violation List" issued by the National Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
drug drug drug enterprise enterprise enterprise, Ltd.
and Putting the Enterprise on the Violation List" issued by the National Organization for Drug Procurement There are serious defects in aspects such as stability inspection, etc.
It is comprehensively determined that the company does not meet the drug production management standards, and the production and sales of glimepiride are now suspended .
In accordance with the relevant provisions of the "National Centralized Drug Procurement Document (GY-YD2019-2)" of the Joint Procurement Office, Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
purchase purchase purchase, Ltd.
's selected product, Glimepiride Tablets, has been revoked for listing in Shanxi Province (1mg*10/tablet* 3 boards/box 1.
61 yuan; 2mg*10 tablets/board*3 boards/box 2.
74 yuan); at the same time supplement Shandong Xinhua Pharmaceutical Co.
, Ltd.
Glimepiride Tablets in Shanxi Province (1mg*10/tablet*3 Board/box 1.
61 yuan; 2mg*10 pieces/board*3 boards/box 2.
74 yuan)
.
On January 29, 2022, the State-organized Drug Joint Procurement Office issued an announcement stating that the results of the second batch of state-organized centralized drug procurement have been launched in various places in April 2020
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
.
Recently, the drug regulatory department found in an unannounced inspection that the glimepiride tablets produced by Guizhou Shengjitang Pharmaceutical Co.
, Ltd.
, the second batch of products selected for centralized drug procurement organized by the state, did not meet the quality management standards for drug production
.
On January 28, 2022, the Guizhou Provincial Drug Administration released public information, suspending the production and sales of glimepiride tablets by the company according to law, and further investigation and handling
.
On February 23, 2022, Shanghai Sunshine Pharmaceutical Purchasing Network announced that the glimepiride tablets previously produced by Shengjitang had been disqualified from the second batch of national procurement due to non-compliance with the quality management standards for drug production.
The supply of pharmaceutical substitutes will be officially implemented on March 1
.
medicine medicine medicine The supply of pharmaceutical substitutes will be officially implemented on March 1
.
